Active Pharmaceutical Ingredient CDMO Market Size to Hit Around USD 179.66 BN By 2032
The global active pharmaceutical ingredient CDMO market size was exhibited at USD 92.19 billion in 2022 and is projected to hit around USD 179.66 billion by 2032, growing at a CAGR of 6.9% during the forecast period 2023 to 2032.
Key Takeaways:
Active Pharmaceutical Ingredient CDMO Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 98.55 Billion |
| Market Size by 2032 | USD 179.66 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 6.9% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, Synthesis, Drug, Application, Workflow, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Cambrex Corporation; Recipharm AB; Thermo Fisher Scientific Inc. (Pantheon); CordenPharma International; Samsung Biologics; Lonza; Catalent, Inc.; Siegfried Holding AG; Piramal Pharma Solutions; Boehringer Ingelheim International GmbH |
The growth can be attributed to factors such as increased drug R&D, the rising incidence of chronic diseases, the expanding importance of generics, and the increasing consumption of biopharmaceuticals. Moreover, the rising adoption of development and manufacturing outsourcing services as an effective cost-containment mechanism is further fueling market growth.
COVID-19 significantly impacted the supply chain of active pharmaceutical ingredients (API), causing some level of disruption in raw material supply and availability, shipping delays, and costs. However, the demand for new treatment options and an increase in the approval rates of new drugs supported the market growth during the pandemic. The growing burden of chronic diseases such as cancer, heart disease, and others is improving the demand for new treatment options. This is expected to drive demand for new API in the coming years and hence support the market in the post-pandemic period.
Pharmaceutical companies have been increasing the amount of discovery, development, and manufacturing work they outsource over the last couple of decades. However, the urge to outsource is not uniform in the biopharma industry. Small biotechnology companies frequently rely on a Contract Development and Manufacturing Organization (CDMO) to produce their development products as they go through the pipeline.
CDMOs are proving to be extremely beneficial to the pharmaceutical and biotech industries since they provide prospective capabilities and cost savings over in-house manufacturing. There is a substantial link between corporate size and outsourcing in general. Small and medium-sized businesses (SMEs) have fewer stakeholders and organizational hurdles in the decision-making process, allowing for more fluid decision-making. As per IQVIA, the market for medicines would expand at 3-6% CAGR by 2025, reaching a total value of about USD 1.6 trillion, excluding spending on COVID-19 vaccines. This is expected to create opportunities for market growth in the coming years.
Product Insights
The traditional active pharmaceutical ingredient segment dominated the market and accounted for the largest revenue share of 39.19% in 2022. The market for traditional APIs is projected to expand at a promising CAGR of 4.2% during the forecast period, owing to rising pharmaceutical R&D, growing cases of chronic diseases, increasing adoption of generics, and rising uptake of biopharmaceuticals.
Furthermore, a rise in the adoption of high-tech therapeutics, the evolution of personalized medicines, and the emergence of innovative & novel delivery systems are factors likely to also boost market growth. The growing trend of outsourcing by large pharmaceutical firms will drive the demand for traditional API CDMO. Increasing investments in R&D pertaining to production processes for APIs is likely to propel segment advancement.
The antibody-drug conjugate segment is anticipated to register a lucrative growth rate of 13.9% over the forecast period. The efficacy of antibody-drug conjugates (ADC) and checkpoint inhibitors in the fight against cancer is having a significant impact on ADC R&D. Besides, new and intriguing use cases of antibody-drug conjugates are also being actively studied. The ADC biopharmaceuticals sector has experienced a significant increase in R&D into new uses of ADCs, both in terms of combination medications for cancer therapy and the application of the drug class to treat diseases other than cancer.
Synthesis Insights
The synthetic segment dominated the market for active pharmaceutical ingredients CDMO and held the largest revenue share of 73.19% in 2022. This is due to the increased availability of raw materials and the ease with which these molecules may be synthesized. Many synthetic molecules are also expected to go off-patent in the coming years, which is anticipated to boost growth.
The biotech segment is projected to register the fastest growth rate of 7.0% over the forecast period. Factors such as rising demand for biopharmaceuticals and higher molecular efficiency are propelling segment growth. Furthermore, large investments in the biotechnology and biopharmaceutical industries can be ascribed to segment advancement. Biotech active pharmaceutical ingredients cover a small portion of the active pharmaceutical ingredient market. However, given the explosive growth of the biopharmaceutical industry and the increasing use of biotech drugs, the biotech-active pharmaceutical ingredients space is expected to have a positive outlook.
Drug Insights
The innovative drugs segment dominated the active pharmaceutical ingredient CDMO market and accounted for the largest revenue share of 73.7% in 2022. Increased FDA approvals for new molecular entities, the high cost of innovative active pharmaceutical ingredients relative to generic pharmaceuticals, and the strengthening focus on R&D are all contributing to segment growth. Many unique molecules are present in the pipeline as a result of extensive research in this subject and are projected to be launched during the forecast period.
On the other hand, the generic drugs segment is anticipated to witness the fastest CAGR of 8.6% during the forecast period. This is largely due to the patent expiration of branded drugs and the cost-effectiveness of generics. The generic sector is expanding as a result of the growing number of patents that are scheduled to expire. According to the U.S. FDA, approximately 158 drug patents expired in 2021, presenting a large market opportunity for generic pharmaceuticals. Out of 156 patents, 44 would be readily available to generic manufacturers. All these factors are likely to propel segment growth.
Application Insights
The oncology segment dominated the market for active pharmaceutical ingredients CDMO and accounted for the largest revenue share of 35.9% in 2022. The market is growing due to the rising number of cancer cases globally. According to the WHO, cancer is a leading cause of mortality and accounted for 10 million deaths in 2021 across the globe. The rising demand for new cancer therapies is anticipated to increase as a result of the steady increase in cases. The growing presence of novel drugs in cancer is expected to create opportunities for the segment.
The glaucoma segment is expected to expand with a substantial CAGR of 7.5% across the forecast period. This is largely attributed to the rising prevalence of diabetes, the growing elderly population, and the increase in healthcare spending globally. According to the WHO, glaucoma is the world's second-largest cause of blindness. Thus, a rapidly growing need for lowering the disease burden of glaucoma is likely to support market growth of this segment in the near future.
Workflow Insights
Based on workflow, the commercial segment dominated the market for active pharmaceutical ingredients CDMO with a revenue share of 87.19% in 2022. The segment growth is supported by the high disease burden globally, which promotes the demand for APIs. According to the CDC in 2021, 695,000 people died in the U.S. due to cardiovascular diseases. Thus, rising mortality rates are boosting CDMO operations for APIs worldwide. Global market players are expanding their presence to improve their API manufacturing capabilities. For instance, in June 2022, Merck opened an HP-API production facility in Wisconsin, U.S. to improve its manufacturing capability for producing cancer drugs.
The clinical segment is anticipated to witness the fastest CAGR of 7.3% in the market for active pharmaceutical ingredients CDMO during the forecast period. This is largely attributed to a record number of molecules being in the preclinical and clinical development pipelines of all sorts, as well as increased R&D spending. The growing demand for new treatment options worldwide is likely to improve the frequency of clinical research, hence promoting segment growth.
Regional Insights
Asia Pacific dominated the active pharmaceutical ingredients CDMO market and accounted for a revenue share of 49.12% in 2022. Furthermore, the region is anticipated to register the fastest CAGR of 9.2% through the forecast period. Factors such as improved regulatory framework, high scope for cost savings, increased complexity, and robust drug pipelines are expected to drive the regional market. Furthermore, the availability of skilled workforce at a lower cost than in developed economies such as the U.S. is poised to propel the market. China holds the largest share in the Asia Pacific market, primarily due to the high pharmaceutical R&D investment.
Increasing regulatory focus on quality control for manufacturing is another key factor expected to drive the market over the forecast period. North America held a 23.12% share of the global market in 2022, aided by the presence of several established biotechnology and pharmaceutical companies. Furthermore, growing R&D investments by life sciences and pharmaceutical companies are anticipated to increase the demand for API contract manufacturing in the region. In addition, stringent regulations on manufacturing and quality of products are anticipated to create growth opportunities for domestic contract manufacturing services.
Some of the prominent players in the Active Pharmaceutical Ingredient CDMO Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Active Pharmaceutical Ingredient CDMO market.
By Product
By Synthesis
By Drug
By Workflow
By Application
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Synthesis
1.1.3. Drug
1.1.4. Application
1.1.5. Workflow
1.1.6. Regional scope
1.1.7. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Nova one advisor internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Active Pharmaceutical Ingredients CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing pharmaceutical R&D investment
3.3.1.2. Rising demand for generic drugs
3.3.1.3. Patent expiration
3.3.1.4. Expanding consumption of biopharmaceuticals
3.3.2. Market Restraint Analysis
3.3.2.1. Compliance issues while outsourcing
3.3.3. COVID-19 Impact & Recovery Analysis
3.3.4. Industry Analysis - Porter’s Five Forces
3.3.5. PESTLE Analysis
Chapter 4. Active Pharmaceutical Ingredients CDMO Market: Product Segment Analysis
4.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
4.2. Active Pharmaceutical Ingredients CDMO Market: Product Market Share Analysis, 2022 & 2030
4.3. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.3.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market, 2020 - 2032 (USD Million)
4.4. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.4.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market, 2020 - 2032 (USD Million)
4.5. Antibody Drug Conjugate (ADC)
4.5.1. Antibody Drug Conjugate (ADC) Market, 2020 - 2032 (USD Million)
4.6. Others
4.6.1. Others Market, 2020 - 2032 (USD Million)
Chapter 5. Active Pharmaceutical Ingredients CDMO Market: Synthesis Segment Analysis
5.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
5.2. Active Pharmaceutical Ingredients CDMO Market: Synthesis Market Share Analysis, 2022 & 2030
5.3. Synthetic
5.3.1. Synthetic Market, 2020 - 2032 (USD Million)
5.4. Biotech
5.4.1. Biotech Market, 2020 - 2032 (USD Million)
Chapter 6. Active Pharmaceutical Ingredients CDMO Market: Drug Segment Analysis
6.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
6.2. Active Pharmaceutical Ingredients CDMO Market: Drug Market Share Analysis, 2022 & 2030
6.3. Innovative
6.3.1. Innovative Market, 2020 - 2032 (USD Million)
6.4. Generic
6.4.1. Generic Market, 2020 - 2032 (USD Million)
Chapter 7. Active Pharmaceutical Ingredients CDMO Market: Workflow Segment Analysis
7.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
7.2. Active Pharmaceutical Ingredients CDMO Market: Workflow Market Share Analysis, 2022 & 2030
7.3. Clinical
7.3.1. Clinical Market, 2020 - 2032 (USD Million)
7.4. Commercial
7.4.1. Commercial Market, 2020 - 2032 (USD Million)
Chapter 8. Active Pharmaceutical Ingredients CDMO Market: Application Segment Analysis
8.1. Active Pharmaceutical Ingredients CDMO Market: Definition & Scope
8.2. Active Pharmaceutical Ingredients CDMO Market: Application Market Share Analysis, 2022 & 2030
8.3. Oncology
8.3.1. Oncology Market, 2020 - 2032 (USD Million)
8.4. Hormonal
8.4.1. Hormonal Market, 2020 - 2032 (USD Million)
8.5. Glaucoma
8.5.1. Glaucoma Market, 2020 - 2032 (USD Million)
8.6. Cardiovascular
8.6.1. Cardiovascular Market, 2020 - 2032 (USD Million)
8.7. Diabetes
8.7.1. Diabetes Market, 2020 - 2032 (USD Million)
8.8. Others
8.8.1. Others Market, 2020 - 2032 (USD Million)
Chapter 9. Active Pharmaceutical Ingredients CDMO Market: Regional Analysis
9.1. Active Pharmaceutical Ingredients CDMO Regional market share analysis, 2022 & 2030
9.2. North America
9.2.1. North America Market estimates and forecast, 2020 - 2032
9.2.2. U.S.
9.2.2.1. U.S. Market estimates and forecast, 2020 - 2032
9.2.3. Canada
9.2.3.1. Canada Market estimates and forecast, 2020 - 2032
9.3. Europe
9.3.1. Europe Market estimates and forecast, 2020 - 2032
9.3.2. UK
9.3.2.1. UK Market estimates and forecast, 2020 - 2032
9.3.3. Germany
9.3.3.1. Germany Market estimates and forecast, 2020 - 2032
9.3.4. France
9.3.4.1. France Market estimates and forecast, 2020 - 2032
9.3.5. Italy
9.3.5.1. Italy Market estimates and forecast, 2020 - 2032
9.3.6. Spain
9.3.6.1. Spain Market estimates and forecast, 2020 - 2032
9.3.7. Denmark
9.3.7.1. Denmark Market estimates and forecast, 2020 - 2032
9.3.8. Sweden
9.3.8.1. Sweden Market estimates and forecast, 2020 - 2032
9.3.9. Norway
9.3.9.1. Norway Market estimates and forecast, 2020 - 2032
9.4. Asia Pacific
9.4.1. Asia Pacific Market estimates and forecast, 2020 - 2032
9.4.2. Japan
9.4.2.1. Japan Market estimates and forecast, 2020 - 2032
9.4.3. China
9.4.3.1. China Market estimates and forecast, 2020 - 2032
9.4.4. India
9.4.4.1. India Market estimates and forecast, 2020 - 2032
9.4.5. South Korea
9.4.5.1. South Korea Market estimates and forecast, 2020 - 2032
9.4.6. Australia
9.4.6.1. Australia Market estimates and forecast, 2020 - 2032
9.4.7. Thailand
9.4.7.1. Thailand Market estimates and forecast, 2020 - 2032
9.5. Latin America
9.5.1. Latin America Market estimates and forecast, 2020 - 2032
9.5.2. Brazil
9.5.2.1. Brazil Market estimates and forecast, 2020 - 2032
9.5.3. Mexico
9.5.3.1. Mexico Market estimates and forecast, 2020 - 2032
9.5.4. Argentina
9.5.4.1. Argentina Market estimates and forecast, 2020 - 2032
9.5.5. Colombia
9.5.5.1. Colombia Market estimates and forecast, 2020 - 2032
9.5.6. Chile
9.5.6.1. Chile Market estimates and forecast, 2020 - 2032
9.6. MEA
9.6.1. MEA Market estimates and forecast, 2020 - 2032
9.6.2. South Africa
9.6.2.1. South Africa Market Estimates and forecast, 2020 - 2032
9.6.3. Saudi Arabia
9.6.3.1. Saudi Arabia Market estimates and forecast, 2020 - 2032
9.6.4. UAE
9.6.4.1. UAE Market estimates and forecast, 2020 - 2032
9.6.5. Kuwait
9.6.5.1. Kuwait Market estimates and forecast, 2020 - 2032
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Profiles/Listing
10.3.1. Cambrex Corporation
10.3.1.1. Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Recipharm AB
10.3.2.1. Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Thermo Fisher Scientific Inc. (Pantheon)
10.3.3.1. Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Samsung Biologics
10.3.4.1. Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Lonza
10.3.5.1. Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Catalent, Inc.
10.3.6.1. Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Siegfried Holding AG
10.3.7.1. Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Piramal Pharma Solutions
10.3.8.1. Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Boehringer Ingelheim
10.3.9.1. Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. CordenPharma International
10.3.10.1. Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers